^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Pusintin (bevacizumab biosimilar)
i
Other names: TAB008
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
TOT Biopharm
Drug class:
VEGF-A inhibitor
Related drugs:
almost2years
Bevacizumab biosimilar candidate TAB008 compared to Avastin in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study. (PubMed, J Cancer Res Clin Oncol)
TAB008 is similar to Avastin in terms of efficacy, safety, and pharmacokinetic parameters, with comparable immunogenicity.
Clinical • Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR wild-type
|
carboplatin • paclitaxel • Pusintin (bevacizumab biosimilar)
4years
[VIRTUAL] Biosimilar TAB008 compared with bevacizumab in advanced non:squamous, non-small cell, EGFR wildtype lung cancer patients (ESMO Asia 2020)
Patients received 4-6 (3 week)cycles of paclitaxel/carboplatin plus TAB008 or Avastin® at 15mg/kg intravenously, followed by 7.5mg/kg maintenance dose until disease progression, unacceptable toxicity, or death. Legal entity responsible for the study: TOT BIOPHARM. Funding: TOT BIOPHARM.
Clinical
|
EGFR (Epidermal growth factor receptor)
|
carboplatin • paclitaxel • Pusintin (bevacizumab biosimilar) • theralizumab (TAB08)
4years
[VIRTUAL] Biosimilar TAB008 compared with bevacizumab in advanced nonsquamous, nonsmall cell, EGFR wildtype lung cancer patients (ESMO Asia 2020)
Patients received 4-6 (3 week)cycles of paclitaxel/carboplatin plus TAB008 or Avastin® at 15mg/kg intravenously, followed by 7.5mg/kg maintenance dose until disease progression, unacceptable toxicity, or death. TAB008 is similar to bevacizumab(Avastin®) in terms of efficacy, safety, and pharmacokinetic parameters. TOT BIOPHARM.
Clinical
|
EGFR (Epidermal growth factor receptor)
|
carboplatin • paclitaxel • Pusintin (bevacizumab biosimilar) • theralizumab (TAB08)
4years
[VIRTUAL] Biosimilar TAB008 compared with bevacizumab in advanced nonsquamous, nonsmall cell, EGFR wildtype lung cancer patients (ESMO Asia 2020)
Patients received 4-6 (3 week)cycles of paclitaxel/carboplatin plus TAB008 or Avastin® at 15mg/kg intravenously, followed by 7.5mg/kg maintenance dose until disease progression, unacceptable toxicity, or death. TAB008 is similar to bevacizumab(Avastin®) in terms of efficacy, safety, and pharmacokinetic parameters. TOT BIOPHARM.
Clinical
|
EGFR (Epidermal growth factor receptor)
|
carboplatin • paclitaxel • Pusintin (bevacizumab biosimilar) • theralizumab (TAB08)
Share via
